**AMENDMENTS TO THE CLAIMS** 

What is claimed is:

1. (Currently Amended) A method for treating sickle cell anemia or treating

thalassemia in a patient in need thereof comprising administering to a patient in need thereof, a

therapeutically effective amount of N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide

mononitrate or a mixture of two or more thereof, and at least one antioxidant hydralazine compound

or a pharmaceutically acceptable salt thereof.

2-4 (Cancelled)

5. (Currently amended) The method of claim [[4]] 1, wherein the hydralazine

compound is hydralazine hydrochloride.

6 - 20. (Cancelled).

21. (New) The method of claim 1, wherein the hydralazine compound is selected from

the group consisting of budralazine, cadralazine, dihydralazine, endralazine, hydralazine,

pildralazine and todralazine.

22. (New) A method for treating thalassemia in a patient in need thereof comprising

administering to a patient in need thereof, a therapeutically effective amount of N-hydroxy-L-

arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof, and at

least one antioxidant.

2

Application No. 10/594,990 Docket No.: 0102258,00375US2

Amendment dated July 20, 2009 Reply to Office Action of April 21, 2009

23. (New) The method of claim 22, wherein the antioxidant is selected from the group

consisting of budralazine, cadralazine, dihydralazine, endralazine, hydralazine, pildralazine and

todralazine.

24. (New) The method of claim 22, wherein the antioxidant is a hydralazine compound

or a pharmaceutically acceptable salt thereof.

25. (New) The method of claim 24, wherein the hydralazine compound is hydralazine

hydrochloride.

3